<SEC-DOCUMENT>0001193125-11-089246.txt : 20110405
<SEC-HEADER>0001193125-11-089246.hdr.sgml : 20110405
<ACCEPTANCE-DATETIME>20110405164707
ACCESSION NUMBER:		0001193125-11-089246
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20110330
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20110405
DATE AS OF CHANGE:		20110405

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		11740610

	BUSINESS ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of Earliest Event Reported): April&nbsp;5, 2011 (March 30, 2011) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>ARCA biopharma, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in Charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-22873</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>36-3855489</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8001 Arista Place, Suite 200,
Broomfield, CO 80021 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code) </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(720) 940-2200 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s Telephone Number, Including Area Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not
Applicable </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former Name or Former Address, if Changed Since Last Report) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;1.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Entry into a Material Definitive Agreement </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On March&nbsp;30, 2011, ARCA biopharma, Inc. (&#147;ARCA&#148;) and the University of Cincinnati agreed to extend the term of the Exclusive Option
Agreement dated December&nbsp;2, 2009 (filed as Exhibit 10.27 to the Company&#146;s Annual Report on Form 10-K for the period ended December&nbsp;31, 2009), as amended, that gave ARCA an option to license exclusive, worldwide rights to certain
patent rights relating to genetic polymorphisms of adrenergic cardiac receptors.&nbsp;The rights include those for developing and commercializing diagnostics for the receptor polymorphisms that may indicate which patients will respond most favorably
to Gencaro. The period of the option has been extended to April&nbsp;15, 2011.</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The letter in regard to the agreement term extension is filed
as Exhibit 10.1 to the Current Report on Form 8-K, and the description of the extension is qualified in its entirety by reference to such exhibit. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit&nbsp;No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Letter in regard to agreement term extension, signed March&nbsp;30, 2011, of the Exclusive Option Agreement dated December&nbsp;2, 2009, as amended, between ARCA biopharma, Inc. and
the University of Cincinnati.</FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: April&nbsp;5, 2011 </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA biopharma, Inc.</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(Registrant)</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Christopher D. Ozeroff</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name: Christopher D. Ozeroff</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title: Senior Vice President and General Counsel</FONT></TD></TR></TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit&nbsp;No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Letter in regard to agreement term extension, signed March&nbsp;30, 2011, of the Exclusive Option Agreement dated December&nbsp;2, 2009, as amended, between ARCA biopharma, Inc. and
the University of Cincinnati.</FONT></TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>dex101.htm
<DESCRIPTION>LETTER IN REGARD TO AGREEMENT TERM EXTENSION
<TEXT>
<HTML><HEAD>
<TITLE>Letter in regard to agreement term extension</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.1 </B></FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center">

<IMG SRC="g173931g66d83.jpg" ALT="LOGO"> </P>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>8001 Arista Place, Suite 200 </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Broomfield, CO 80021 </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Phone: 720-940-2200, Fax: 720-208-9261
</I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;31, 2011 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Geoffrey Pinski </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director of Intellectual Property </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">University of Cincinnati </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Office of Intellectual
Property </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">51 Goodman Dr, Suite 240 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cincinnati, Ohio 45219-0829 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dear Geoffrey,
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">When countersigned by the University of Cincinnati, this letter will extend the Exclusive Option Agreement between ARCA
biopharma, Inc. and the University of Cincinnati dated December&nbsp;2, 2009 to April&nbsp;15, 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Please sign below
indicating your agreement to the above. Feel free to contact me if you have any questions. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="100%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Best regards,</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Christopher D. Ozeroff</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Christopher D. Ozeroff</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">SVP and General Counsel</FONT></TD></TR></TABLE></DIV> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>ACCEPTED AND AGREED:</U></FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">UNIVERSITY OF CINCINNATI</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Geoffrey Pinski</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Geoffrey Pinski</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 30, 2011</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g173931g66d83.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g173931g66d83.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`;`$A`P$1``(1`0,1`?_$`,D```$$`@,!`0``````
M```````'"`D*!08!`P0+`@$!```&`P$```````````````$$!08'"`(#"0H0
M``$$`0,#`@('!00'!@8#``$"`P0%!@`1!R$2"#$300GP46$B(Q05<9$R%@J!
ML4)2P6)R,R07&*&2);9W.=%#<],T-29V-Q$``0,#`@,$!0<(!P@#``````$"
M`Q$$!2$&,1('05$B,F%Q$Q0(@9&QP=$C":'A4G*R,Q46\/%"8H(T)9)#4V-S
MLT1D5)15_]H`#`,!``(1`Q$`/P"_):V<6HARK"PE,P8$*.Y+F39+C;,:+&80
MMU^3(></8RPRVC=2E=!JFY;+6&"L)<QEI&0XFWC5\KW+HUJ)6OR';#"^:1&,
M3F<Y:(B<:D;7*_S`?R$]^IXHHX-I'CK6VO*;]+WY24=NBZFHCNL27&-_X7'E
MCN_R`:\T^L7XA6+Q65EP/2VW]Y2"J/NY&HYG,NC4;&JT6JHNM?D,T[:Z1SW5
MHW)YIZI;K3[MJT<M>%5HORT^<0!GS>\C)BR&+;&`%*/8D8I#V2">B-ER%+)`
M^L[ZUB3X\_B6GD=';W6+]HY?`WW&)51.ROBU+XAZ3[07]['/7_JN^PR#?F7Y
M(K0H_KN,]R=B0C$8).VX!Z%[72WX\?B:>C(TO,8D_(JK_I\7'7^\=<O2S9R)
MS113T3_FN^P][_F!Y'QTQBJ\QO\`XB*U)'=B$$;I<[QN-GB-MTZJ%W\<'Q16
M+;9)[S&<\L2/7_3XM6JJI^EIP4EX^FVR53QQSJM?^,OV&+=\T/)%M+O_`(QC
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M/70&8]Y?V?NT`>\O[/W:``ZLG8;;]3Z?5Z_NT!^N][_*?^[O_=H`[WO\I_[I
MT!V*4YL-@-]_]!^&^@.HN.CU&W[4G0''O+Z^G3UZ>G[=`'O+^S]V@#WE_9^[
M0![R_L_=H#'6M]5T,15A>VM52P$;ER;<SXM7#0$C=2E29CK+0"4]3UT`DCWD
M[XY,250WO(+A!J4A1;5%5RK@:)7N)]4!AS(`L*!]00#H!0<=Y!PK*T![&LVP
M[(V5'=*J#(Z:X3VK`+:?<KK"2DDC[.N@-O6MQ)'38'IZ>I^K]NV@.OWE_9^[
M0![R_L_=H`]Y?V?NT!KUYEU#CLFDBWF14%%)R.S:H\?BW5I!K)&073[;TANG
MHFICS*[:W7%CN.(CL=[JDHW[2-`;#[R_L_=H`]Y?V?NT`>\O[/W:`]>@(U/F
M"\HV%3`QOBNJ?<C-Y'%=R')76G-C*J8<DQ(-4XD=?R\N8%+<'HL-`:\Q_P`1
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M]T*RUE27F65C^54[:K\O`S^3\=-P8N)[,`?F\-JY/\/M_>7*GI62#]T!(2-R
M3\=7/OOIG9P0XR=UN[QX.!Z)1*JKIKA*>OPZ^A4*?C\Y[7VJ2.=SME5/1P3[
M30LNX]_1J>LCN1RF=9L_KDT*)#C<-U3C-/%5N-D!<=*W^IV`=2=^NL=;WZ1+
MB<7#;R,@2]DC]JK554Y6IJO-X=%IP37UE=Q&8;*];B.JL;5NO?\`F$"N<0D-
MB3(0VMN-'"0XZK<(]U8/8TGINMY?^4;D#J=D]=:OY+::PPRWZQR-M8U7Q*JM
M:[]3O^9"\;?)++1:JGJ-?Q/*KWC_`">ERVAD.Q+BCG-38RFU;!]M!(DP9`'W
M7(LZ-W-.).XV5OL=AJ/3W>.<V%O.RWEA9EM\A:7C47E5?&Q%:JHO"NGSE1SU
MM!EL3)C+UK7M<E$6FJ*J:+^<L38CD$3+,7Q_*(([8>0U%?<QD$@EMJPBM20T
M2DE)+1<*>G3IKZ6-D;D@WAM'';HMVJV._M62T5$1:N2BUI76J=YI)>V,F-O[
MBRD6KXYG(;%JZ26#0!H"'CYWWE&KQU\),JQBBGKA\@>0$H\38O\`EW.V;'HK
M!G\WR!;,A)+@;BXLAR(5`#M<G(.^^VAS:QS^`W/^G<\B49]XNYCX]6<U"KKQ
M]RM;F-PU.@N)XWSQZ7;UK$9LD=T.CR=BQBI*=TMH4VG?TT#HW,2JEA/0X!H!
M)^<.'<9Y^XMS#B',[#*:O&,VKFJVVGX5D<_$\HAMQYT:Q8>I<AK"F;6R?S,1
M`6I.X6UN@@@Z`K(?,9^6#R-X=<'Y9Y(^-WEYY(2L7P:15R\XP+-N3<BD3XU)
M;64.F%OCV2T]E4*DKK9T]KW(TJ,M:V-REW=/:1R:U7+1"(SQ!?\`+3S5\CN-
M?'2N\J.;<?.;/VR[/))_)F=6C>/8SC5/+R2_G-0&LDB*F2A!@%N.RMQ*527D
M=Y"4G0YK$Y$JM"R]&^0UQ,:M;5OYA>:=I?+;)_76^5Q#;$E23O(16J@RA]Y6
MQ(4\2=O70ZB+3S%XU^8M\H&[Q'D/BCR^Y2Y/X&RF[_1:NRS.=-R6NILC0TJP
M8Q7D/#,DD7U.LW42.\J'-@NQ_?#+K8#+O9W`35_*P^:50>?&/7F&YQ2U.!^0
MN`5,:VR6@JGW5X]FN-.+:A#-\.1+<<FQ8[,Q269\!PN+B./-J2XMI8(`E\WW
M&X^W^_\`T^N@,7;6]/2U%G>7EE!J*2G@S;2UM[.8S7UM;7UC:Y,V?/GON-,Q
M(,1IE2G75*"$H2HD[:`JP^:_SW^0,WSI?`WR[L>=N)]K<MXG`YBE4)O\DS.\
MG2OR$>'Q)A<EM3"83\E7_#V,]IU3R.UU#"&C[I`6?@+Y)_(_.;4'E;YFWD)R
MIR=F=TE-F[Q!3Y]9OU]`'MW&Z_)\H5(D,N36D*[7HE,Q%BL'[J'U@#8!_1^2
ME\LP4PIAXPT2MVDM*MU99G9OMTC_`'YM%9,MSWEGUV2!H"*[S%_I^&\/QZZY
M*\$,WRV'?4L.18N<+9->O&5<QXX5(<AX%G4-4"PCWBD;HC1;$/)D+V0)""1N
M!I_]/#RKR$_Y`>2G$G(^6Y_:2XO&]#:P\:SJ^R*UD8W:XCFLBER2O9J\BFR'
M:F8R[>AJ4D)0M"FRE6_:-`6TM`&@#X$_4-_V_8/M.@*8/SW?,B^N?-?C/CWC
MF[+,?PX>H\PARH;R5LIYKLI57D\MT]F^TJBIZ^!!._WF_P`Q)1M]XZ`MQ<!<
MOT//O"G%W,^,.M.4?)V#8_F<1++A<3%?N(33UG6J5NH>Y5V1=CK!.X6T1\#H
M!7-`&@,AH"&[S\8_,<XT#8/57'E0@@GH$F\R3T'H/7?]H'U:\2_Q%GO?UVQE
MO&M7KMZWHG9K=7:&RO1Y*;;E?_[;_P!B,0+%,8=,EE$MI]HE0)0I`;6I)ZCV
M5)([R?7<'<:U7Z?;2EDO977S7>\\Z.8ZBT;37FKPTXEWY'*)%<K&Y=*?U#UL
M&PR'FT5,/W&XF8064B))=+2(N3Q6``IF2-A^4NX[>P2L]'D`;]4DZ]%=B[+P
M^\,9':VJ-BWK&U$C6E$N>Y'+WUTUK6IBG.Y>ZQ]PL[JNMU7YOS+V]PN=1@SM
MI@%A46+*:NWQ2Y?5`59.,1]V)Z$//5ZWWE(90RMU(6"#MN-_CK/^+V`S(;"N
ML#EXV6V3QMRBH]:(JLT5R(JTKP7@69-E%ARZ7+*K;S,YJ)KJE=5H;798-2YC
M8X6Q&L:J774],S77*(TR+(6M,!QM_P#+)2VM1<#ZRM)*3MTU?&6Z>8+=V5PU
M_C[ABVEA"QKV53Q-C=S4I7O52GIE;FVA?-146617)ZE1$^H3#)\">RS(,BR&
MP4JFQ6N?=9?L)#`;+4*"EJ*S#@15C=R2EED-H21[:2K?6(-U]-KK>>X[S<N4
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M#\K*D@=J>\E21V]=^I`^`/\`;]0ZZ`JI^:_'5_\`-3\[/)+B_#K*:OCSP6\;
M<RK\>>K%E<*[\A9[?Y^+6I4`MIPRKZ.N`\D;K4W6*'0'4"8B5&LU[5(MODR^
M10\<_._C47,MVKQ'F1J;PKF3#SOM,,3\EDL+Q25.0?NH56YC`C,GH.Q+[GVZ
M(<IO)\I?V&_^(;'KT^K8[?WC425.=`&@(X/F\=/EL^69'JGC^N(.P.Q_G#&^
MH"@1N/K]1H=D7G0JD_(LV'S*^&DI2E*?Y-Y?(`&VQ3@=L0=_7_$?[-03B3+_
M`"*7U=1)(BS^=-C-3D7RU?)-VS9:==QRJP[*J=QU(4J/>5&>XV8;L51^\W)=
M8?=8!'P>/VZ`J6?)WRF^Q;YD?C*N@=?9.29!E&(73,<K")>.7>$9$;./(2GH
MJ.VN$U(._0.1T*]4C0'T'R=^O[?4I/H3L24].J=M`5//Z@'SVN'[R/X-\:7;
MD"HC5U9D?D#8UTM33EK)G=ECC'&TB3'(6*R+`2W964<J"7U.L-+2I*7$D!2O
MZ??P8J*O$+/S<Y%I$3,ERR1;8IP3'L8H=5C>,5[IK,ISR"AU*FV[?*+1E<&-
M(1LZS!BN`'\=>X%GGXD_%6VY]2=AMMU]!OU_;H`T!^5)"AL1Z'<?W?\`:#MH
M"*9GPFROCOYK=7YC<64-+$XFY6X1S/%?(`(M85?*B\CJ>K7:#((6/C:5:.90
M*B()CS8[4.LK<7]Y:B0)6]`&@$>\@^9L=\=^$.4N<,M6A%#QCA=WE4MM:NPS
M9,"(LU=6T?C)MK9;$9L>I6Z-`4./)3Q7Y,_Z/.'?F'YZ_:3LL\I>:N4KG/Q,
M[W8U969?.=MN-;!OJ5MMW2Z>VV<6>U3+T4#8`:`L#_T[/D2<X\<N0O'&ZGEZ
M^X)RP7F,LON]SKW'7(KDFQ8:C-=>V/299$GM].B6Y30^.@+$.@#0&0T!#[YU
M,I>YWHQL"K_EW3#J0!UO,C[022!U.O$C\15$DZ\X^-K8UE_ERV5%7C_FKST<
M#9/I#-R[:EC7R^]O_8C->XSL)M?&98"8UA!"@7*VUC)L8"T_%MM#K1D0^[_,
MRM!!U1.C>5R6,MHHIVVUS:.3E6*5/`J*E*^5?$WBW3CW%1W!:6TLCEB=2=:T
M6H]?#8''EJIFPCIL<-N8#2[);4:8Y)K@W`CN2Y+T,OI=>;:9;;62A9&P'3?7
MH)L:UZ:[ALWY2!]WC<C:/;</5B4C3V?BJGB;IX>XP_DKG*6/-97;DFMUX)V]
MW]-!)E\@VW+60OV<M]Y%"AXHHZA2^V.U!95V,S'THV2].F`>XX5]Q2=@D@=-
M87O>I67ZLY]N0NEY\-[1606_Z*M=R\R]E5T7@5V#$LV_9JYGG<VOSI7YAS>-
M8G`>KTN-]K*VTA0(V2I"NT;K:<1LXVO[0=;/[5V'`VR6XEF:MQR5I7RJB>5/
M5H67+?/F>Y'UYE5?F/98_I^0UDNGR>Z?B0<>4+"0^RE/=-A%M;*$20KN*WX[
MB.BP"22-5B[6PW/@I<7N"=T=M:JB^'5ZHW6C=4U4D?9S0R)/;>==/G&JYS:T
M$`/1\.H(C"D_<_7KKMM[=U)W/N1V)"5Q('<D@A00MS;T(UJ-OO/;.LK.6QVG
M80Q7+55%GNF_?KZ6^%W[1D/;]I)<(CKF5/4FB?:HQ+/XTMZ5(?D.//R'4GN7
M)<[U^I/17H!]G37FMU<FD]]<LUP^1%CDTHO<AF7;20(BI5-)$^HF4\:=_P#D
M)Q3N-O\`^'U^P^K93P^WXC7O-\+CFO\`A[VDYB4;_"(_VGFL.]N3^:K[V?E]
MNOT(+CK/9:P:`;5YA^0E/XK^,W,7/%L\P',$P^QDX_$=*/\`Q3,K$)J,/J$(
M5T>789'.C(*4[DH[CZ`Z`CT^1EP/;<:^'ZN:\T2](Y-\K,SNN9LILIP/ZE*I
M9LMZ-BR)2U[N;3V/S-CU]?U`=/N]0*K?S->"IWBAYY\S8IC:'**KEY=%YCXQ
ME,@LIA4V7S?YLJC7.I0!VT63-RXHVV`4P$D_$`7J/#'GV%Y0^+?"7.<1UER7
MG6"U$G(F6%!?Y#,:YI51EM:X$DE#L/(H$A&Q`Z;'T(T`YSZ==`&@(X/F\?\`
MML>6G_I[7_\`G#&M#G%^\0JD_(L"C\RWAKM25;87S"H@%.X2G`K/=>Q()2"K
MX;Z@G$FG^12^L`2=AU(.QV^&^_\`%_E]/CUU$DBNM_4">8^!XAXZN^)..9)6
M6_*7+U]C4G+J*MF1Y4K#\`QJY8OU2,A+#CIJ[#([^JB1H4=?9(<0'%=O;L2`
MBOR*_EIYW@>3M>9_/&/S\1FN8Y/J>#<%O(:HU^W"R&,8EKR3>P)+:'ZH3J:2
MN-5L.!#ZVWW7U)0%(&@+14J5'KXTF=)V:BQ(TF:^KH$-L16G'W2I1Z?=;:.Y
M^K0'S%.?>2;SG/G#E[E*Q>=F7O)_*.7Y&"M7N=C5U?S$TD1DC?=B'6JCQFQ\
M4H3_`)=0)]$HE#Z17C?QE6<,>/W"O%%1&3$@X!QCA>-)92CVS^:KZ&$BQ?<1
M\'I=B775_P"NLZB2<BU<JBTZ'`-`&@#0!H`]>GU_5H"OC\[_`)!ON5K+Q=^7
M-QS,?_F[RDY)QVTSE,)]0DUG']5=HKZU<YM"BL0'[=R39NDCJBE.Y[=`2%^;
M'B-C_+GR_N2O&##ZB.VC%.**V'Q/"2TE2H>1<55L2UP=#*6D`"1+=HDQE%"1
MW)D+2?7?0%/7Y.GD6YXZ>>'%$NUFJJ\2Y<0_PMG`?=3'C16<R6R<8ERTKV0V
MNGSB-!VW.[;3KB=NIV`^@8E/;NDDG8_'H1T!`(ZC<#0'.@,AH"(OS>DECGBE
M'LQWDJX^I%E,AH.I[F[S)"GIN.G7J/CKQ0_$'O'V7Q"8V6-D3WIMRU\[$=_Y
M=YWFQW2F-KMIS.6M?>W_`+$9BN.,N<AML@8[B#X*@.^71-/;;[G=2ERFP$@?
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M.ST*9KV_C[>-CN7G_>)_:]1+]XW[?\A^*=@`#A]>=AZ#=3QV`^`U[B_#`[F^
M'[:;E1$_TB/AHG%QK)N]J,W/>M2M/;K]0MFL\%MAH"L!\_\`YMM\^S#Q_P#!
M3CZIRO,[&]MHO+G)N'\?PGKC+;:JC.2X6,8[5545IQV7/-8Q:ST(((3[;+BM
MMAH!V&)?-7RC",5QK"\9^5GYWU^.8E04^-4,%''S"&X=/1U\>MKHR`TQV[,Q
M(R4GH#W`]-`0G?.-YHR'RQD<5<SO^&GDUX[R\!@W&#9;E_,6%"GQK(:.]F1Y
M^+U;5JPSLQ90+EN:&DOJ3[K<C9`WT!(#_3A>1QLL,YM\5[VR*YV)6<?EW`HR
MUCN5CN2%JDS&''0?O*17WT:+(6E'H9JE;;^H%G_]GI\/7_3UT`:`C@^;Q_[;
M'EI_Z>U__G#&M#G%^\0IK?*^X?R?G7S+XYXVQ'F3.>`K^VQ[D"Q@<G\;N--9
M?3_H6+S;)V'`]V1&0[&M4-*9D)*B/;.H(3;EHA*C\S;Q[^9MX><>,\CU7GMY
M!\Z<!N38=-EMI_,-MB&48-)L'&HT!S)HE/9R6)F-6LA\1A/9?2(\A2$/-I[D
MK,21$0^1+G/C-9^3608/Y"\=XOE_.&>2!D'"/+_(+LO);#^9ZY@N7.'%B_>E
MUS626C#(G5]BXVJ6\_'<82YW>T-`79MNI4>JNOWB!W=5?7MN/J_LT!K&;UDF
MYPK,*F(I295IBF25D3M.W;*GTTN,RH?4KW'1MH#Y===O07D%<Q)9<HLAB"P"
MSLXR*NU"9_N,_P"`Q/R9W'Q4@GXZ@3Y]2FFL(UM3U-I#7[D.RJZZ?%=WW#L:
M;"8DL.@CILMIT'423?Q_IWF2T.`:`-`&@#0'4\\S&:=DRGFX\5AEQ]^0\I+;
M,=EA"G'G7'%*`"$-H))/0`:`II<2>8EYR/\`-$YT\\F?&3GSR<PK#$7O%?"\
M'AG%G<ABX7&C1V<8IK2WEN,/P8C]EB+$V:VRVI#OOVZW=M@-`3!CYOW(B=M_
ME?\`GBH@'M[N/VQL%*"MAM'2`-P/[-`4ZO*JLL<:\CN3+^!Q;R7P%'R7,[3E
M#!\!Y.I5XYFF)562VTK(*Q;\%*4(<:KKL2!%>C[MEIE*1]Y)T!]!CP>\@X?E
M+XG\'<XLO(<LLQP>M1E;*7$N+A9M1!5!F,1T#JA2,AK9"DA6Q+:TJ^(T`ZS0
M&0T!#OYY.AOG6@^^IK?CVG]QS;O3V"\R+8!LD`JUXB_B+49UYL;AR^&/;5JJ
MIVZW=[P0V3Z3,5VT9J4_SC_^W&:!QOEU94EAZ+41+.<E84)=\DOQVW!MV.1:
MEAQN+WH(W'O*=&_PU9O1S?-IA)&NMV,DO(XE_>HB1HCD\U=?$VE4TX]I.YS%
M275NYKUHSF1=%U]`]/!,DO,PE&PR')9</&:81Y-O+;>_3*YIM!*X]9#8B(99
M_-OK3]UMI*E;#]FM[^G.?W#O1UOD,]E98-N6\M9&HJLC<S1>6->;Q=O8G88I
MR]I;6%LL,3*W;E6BT^E>/K,7R-PCAW+TR]Y+Q"U/'EG$D-Q[6;+9$JBR)2&T
MK3,GP&BB3"LM]@IYE7<M/\:5'KJC=4/A_P!B=9;B\ZE[.G7;N>MEY%NFT3WA
MR<&R,:K:5[^9W&M";V[O+)[<3^'3HL\2IP[43T5TI3U&`QOQISB/:5=;DW(N
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MJT&2YS.K9JWG()DL`A7_``DM34DH)/7VI;0;6I/_`-1.Y&O/#>V:LLK<.]VY
MDK'+YDIV)Z5,QX*WDY>33Q.14]2$UOC7_P#X)Q0.O3#JX=?VNGI]G77OU\,"
M*GP_;3K_`/D1_2XU2WCKN>]5."S+]0M^L\%LF,N[JJQJFMLBO9K-;24-38WM
MQ8R5=D:#4U$5V=8S'W#L$,Q8K*EJ)]`-`5D/E'1+7S5^81Y;_,0RZ+(=H<9G
M3<*XI;F]Q3`=R9LUU-#BJ5N@?RWQ?4QVUA`^Z]:J4>NVX%H)*E@=5K)^)*CL
M3L/0?X1]F@&I><O`#'E'XF\Y\)+92_:Y;@UF]B:UH#BXN:T`1?XA)9[@KM6F
M_K6$D@=4+(]#H"B-\MCR`E>*7FYPOR-=//UM(K+#QOR1'=5[`8Q7,G!BN0"=
MWJ0":*V=BRU))`2]#W^O8#Z,@6A1W0H*2HGL4G8I6-@H%)'0I4E6X/H1Z:`_
M6@(X/F\?^VQY:?\`I[7_`/G#&M#G%^\0JD?(M_\`<MX:_P#Z9S!_Y"M-03B3
M3_(I>FY"P'#^5,%R[C7D"FB9#A6=8]:8ODU)-;2Y&LJ>XB.PYC"NX'VW`TX5
M-N#9;3B4K20I(.HDD?.I\O?&[D;P'\J<DXQ-O;U=C@]_7YOQ!R$PE4:5<XC^
MHHL<&R^!+0D(5:PI$01YW:HAN='>&W;UT.QL;G)5*4+NWRS?-^E\Y_&^BSZ2
M[`@\K8BN-AW-.-1W$`U>:1XS2VKJ)'"BIN@S"#M/B$?<;4XZSU4R=A!S',XD
MB*3L1T/0[$$$'H=B-B!N#_VC0X'SIOF?>-L_QC\T^<^/W*]Z%BF69+-Y.X]?
M[0W&L<(Y#ES;I+4%\]C2TU%H]-KW$[[H<C'?HI),*$RDS::UJ7-OE/\`DI7^
M2W@UPQD3M@W*S+CZBB\1<BQ/=0Y+A93@,2/3M29;8474IO*)J)/0L@)6E\[;
M@$ZB=#U1SJIP)(M#B&@#0#>_)SR=XG\1N*;'F+F.PM86*PKG'\<B0Z"M_6<B
MOL@R>Q16T]-05`D1C83Y#I6X4>XCL99<63LG0"^Q7Q+C1Y2&W6D28[$A+<A(
M:?;#[+;R6WFNXJ0\A+H"AU"5;C?0$57SFO*9'C!X.\AN5%HFNY!YF*>',(6T
MZ4SHPR>-(&77D9L$N*31XBF6ON3MVONL[^N@,[\GSQP/C/X(\0T4^`JOS'DJ
M$YS%FZ7D>U-3:9TTQ*I8,D;!SOJ<1C5\<I5L4J;(V^L"4'O7_F5^\_\`QT!5
M[_J0_'O]2Q/@ORDJ(`7(Q>TG\-YW*#04/T+)EN9#A4N5OLOVX=W#FQDJ7Z&<
M$[[D`CDUJN6B'E_IO/(A,JBYP\5;R:?=HY[',N`0WWD$HJK5R+C>=0(;9V5[
M,*YBP9!2G?8RUG[2.3HG-2J\"T9H=9D-`1`?,,II4;E##KU2%?DK;#$UK3H.
MP3)J+>>_(;^TB/9I<_8DZ\7/Q),!/:]4\/NUR+[I/B8;7T5CN+AZZ\/]ZAL-
MT?ND=BI;%%U]Y<JIZV,1/H&=8M;EF5']V0B.PA>[SBAN0VG^+VT).[CRAT2/
MKZGH#K1?;F3BM\FD=](Z.S>O,JIVHS7E_P`5:&3\U:(G@IW#FZ[DERPCP*YI
M7Y*FK^Y<.N:6%(#QV"YLQ>P$F>XD=7"/NI.R.G76W^!ZMKE+:'#JJV^(B2D,
M35I[1>]?7H6#>X!EP[G5-5%^EYPW7XQ0XJP\M#O8<BR!2"`I<ZR;4N#$=5U[
ME1:TH6H'?9;@^K6RV5WK:LV99[*LI%9.Z%;FY5%HOM4U8GS-3B6=:8!+BZEG
M>G!*)ZD[?E7\B&>S?D&0DX#,B2UM2Z_$:B8VM.P")*I,I"%*&^YW,4;C?KUW
MU7M[=0Y8%V]E+:54R;<1!+(E>U)ID7\C4)"PP#+B*6J<;AS?D1&_:)]R;FD:
M?9,9-&>]AG(8;=@"EPM*@6[`1"LF4N(*7&WH\Z,I22D@]BT*^.L7]4NHEH^^
M;NVR<K+B^1BI1:<JQK5[M.ZJ*5O"XIDD+[2=*I`O*GJ7A^3B-MSS/U9#[DF:
MM*;AE#33\Q';M=,LH#:7'-NU(M$I0.Y9_P!\G??[^V^J/4?J8W=ZME8M,G&E
M$7_Y-.Q?H[>)D#"X1,=]\]/N>X;98S7):G'`2I(2HD#N[E;=>Q(/7O5MV@>N
MYUK-/[7*1\\7G6'L[W*Y%^@ONTC2W1KNWE4L'<&T\G'^'N-:6:GLEU^'4;4E
M!Z*;><A-R'&U#_"IM;Q21]FOI6Z$X=^!Z/;=Q+_-#C(T^>J_6:6;DF2XS]Y*
MU:I[=WY-!5?CZ*V^/:-U`'T('QZD:RR44@?^>MYLT7"7C?;>.&(9##7S)S[%
M10V597S`NSQ+B]QPN91=V:&%%RN<R!AC]-AI5L7@Z^L?=;.@'!?)-XWQ7C[Y
M=/"$K&9$&PF\AHR/D;,;&"MEY2\JO+Z9#D5<IQGN*9./5M9'@J;40IK\OMMH
M"5[0'([_`%0"2"-MCL-P=P"K8[`D;'[-`?.S^:OQ-C_#?GWY*X5B[\(T%AF3
M&<P8U<XT6J1_D&FA9;85"0P0F*]66EN^/;Z*1N/LT!;\^4[YR8AY>^-F$U,[
M)('_`#RXNQJKPSE+$I4MI-Y)>H8Z*RKS>'&=>_,V-/DU?$;>5(;2M+<HNMK(
M5V[@2H;'?;8[_5L=_P!V@(K?G29WC&%_+G\AJK(KFOK;3/*;'<.Q&OD/MMS;
M^_L<LH'Q"JXRW`[+=C0HC\AP(2H(9;)41H=D2>,JE?)?SO%N/_F.<$V^8W,#
M'ZJVK^0,2B6=E);C5J+W)\,M8-%%?EO%ME@VM@6X[)6H!3S[8^.H)Q)EVK5/
MH#J02-B#VG;[01N"!N-P0=O[=1)(AO\`G.^"/_5WXXO9O@=2F9SUP/#M\JPI
M##38L,PQ0,"7E_'Y6VE+K[MA&B";7(Z[6$4-@`/KW*=\*JFG85-/EQ>;5_X)
M^2&/\G)5-E\:9,F+AW,^,M^Z%6V%2)B5"UC02H(5D6'S%_FXNX[RD/,>CJM0
M.<WD^4^@]QCR=@',F$T7(G%V7T6=X7D4)B=3Y#CM@Q8PI+#R`L-NEEQQR),8
MW['F'0AYEQ)0M(4"-1)4CI^:C\N6I\\N(:]S%WJRB\@.+A96?%F1V`#<&Y:L
M$AVUX_R2:&EKC5%\ZTA3#R@M,*:E#O;V%P$"K%X$^8/+GRJ?*'),/YAPS+:?
M"[V77XQSUQ/91G6+RK,-Y:*G/<6BR?8B65OCR7W"TMA;D>SK7%MH=W#2P!>>
MX=YFXPY^P.EY.X>S:BS_``>_BMR*^[H9C4E"%+3W+AV,=*A,JK2(?N/Q9+3+
M[+@(4G0"H_5]OI]O[-`:3R-R+@W$V&W7(/).78_@F%XY%7.N\FR>PCUM3!C-
MI4?Q'Y#C9==<4`EMIH+>>60AM)4H:`J!<[>:3WS6/F0>)W#&#Q+&!XTX/SEC
MKV,U-BTN-/SA^AG#(<MY&R"%MW16Y%!0KC5L-S=R+#4ZISM6^I*0+F,AU#:'
MI#BDMLLH<6XZM2&VV6Q]];KKCA2A"&TC=14H`)&@*9/S#/)3`?F!?,Y\;.`:
MS*JZ5XZ<;<HXEQ?+OQ/#>/93D5_DM=)Y*O(<Q9,.16O-5S5'$D)44NEI2T[H
M<&X%S1F(Q"::C16$1HL9EN+%CM(#;#$=A*6V&64)`2AMIIL)2!T"1L-`=@Z=
M=`,Q^8AQ)0<U>$7DK@.2.Q(4)_BK)LD@VLXLMM55_A,)S,<>LS(D`--+8N:5
MG[ZB/NJ(WZZ'9$M'E#KP)\I)GB+Y2<1\_*:ER,=IK15/R!505^Y*L..\MCBK
MRUEEI(0)DBOC%N=&:W/NOQ&]ANK4":<E4H?1=XZY&P?ES#*'D3C3**7-<'RB
M`S9T&2X_.:L*VPAOM-N)4'&251Y+)5VNLNA#K3@*%I2I)&HDB*-H!OOD5PK`
MYOPEW'EO-P+VN<%IC%NXGN:A6C;;K98EI2/<776#2RT\$G<`A74IU@'XCNB=
MGUUZ>S[5D<V+)QHZ2UD77EEIP]">%NJ*7)M;<LNV<JR\5*VJJB.3OU^E"#+-
M,%R_C6_?Q_,Z*926499#9D()@36A_#*KK$;QIT17P6E1/U@'7@3U!Z4[UZ99
M-VW=Z07,5]"Y?O:*D3VHOA7F[U[.\VSL<_A\U#'<XI]4<WQ(GFKZ?5VU/-4Y
M"N*\RI]9$=#S:G4)V5[C:-BKMV.R@XD=GKZ$ZM7#YJ*SNTG65U&?WE^P[Y+%
MUQK604$<A/RG),AV1W+?6IUQ1Z;G8)0C;?\`P)2`/V:OY_5;,SRSRR21<DB(
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M\3%747J+':Q/PV'<CKUR*CG(O!*>CM)C$)"!V@)2!Z!`[4CH.@'P`]!]FO:>
M&&*WA9!`U&0,:B-:B4Y6IHB4-;4]FKG.9YG.57?K=OU#=/*+@W-/(3C9OC_"
M/('DSQNGJR&!;3\ZXH35C*9]1%CS&96,F1:-.)B5UBN2A;BV]G`64@=-=A$A
M_L/Z=OQTR>SGY%G_`)'^3.<Y=;N%^XRFZO,2DVMH^>GOS9,_'+*6^]M\5NJV
M'0;`:`4GBGY*IX`L8KO`7GOY<\4T*+JON++$Z.VQA5%=&+-C29T:?7-5\*L(
MMX\;V'G!'#G8L]2=`3A-H[$(1N5=J4I*CMNH@`;G;8!1`Z[?'0#)O+CQ)Y#\
MG'L0;Q'R]YW\:J3'ZVYK[ZBX;DUL%G-5V;L5<6?<SI0$UJ55(86AGL64E+JB
MH%770$8"OZ<OQGM)D^UR_P`AO)#*KRTD+F6-W,M</%C/G.[*?G3Y<S&[*7-D
MON;J4MQQ2CZ>@&@.^!_3N\$8G=U^3\9^4/DMQYE%82N%D=':8M&NHCA_B7"L
MJNFIID7O3NDI#A003N#TV`DZQ/Q1Y2QGQ7RKQVD^8W.V19Q?2+%=+Y*6YI7.
M6<-@S)U;(B5=*L(5"?9K8D!R.AQ]2WBB4XKNW"=@(V<K^0)Q]RE<MWW-_F?Y
M5\N6K/>69N4W./39,8.GN>1"=MJ^Z3"0XH]0REL'X[Z`U^5_3=^)3K2TQ>:O
M(6,^2"R^Y8X-)$=0.X4ALXDUNL$>O<#]6@'K^)_RW,T\4N0\=RBJ\Z?)[DW`
M**MMJ]WACD>UKK?!K43:QZNK'904IR1&_0W7$R&`P$$N-I!(&X($I*?N;=NX
MV.XW/<02=_XCU/4_'T]/30$"/,/]/OXP\N<S\@\L)Y0Y0P"IS_))>5/<=8;!
MQ%FAHK6T[9%T*2;954^5'A6-HMZ2&>P)84\4(V2`-`=F(_(;P?B.2]8\`^:W
MEUPM82%)<D/8KDV/LM2)"`H-O284"KJ(,GL[M_Q$+5]N@)OL#QNQP_"<2Q6X
MRR[SJVQS&Z6BL\SR-,87^6SJJNC0Y6278A(9B"VN'V5/O^TD([U=`!H!O?E%
MX1>,WF-1LT_/7%]-E4V%'7'I<QAJ?H<]QM*R%;T675:F;..R%CN,9TO1'#_&
MVK0$0=?\C+E3Q_RJPS'P;\]>4.$Y4]]3KU%D].W:U\QO=)1'N)&/3*ZMO&DA
M.W=+JG5_#?ZP%W9\:_G>+CIJ9/S!_'QB"$>TN\C<),/9"M*1VI<"7,8;BAY2
M0-SL.N@$?R?Y('*WD/:PKWS.^83S%S,]%6IYK'Z3'8%/CU<ZX07/T>%;6-E2
MU^R?NI6U6-K``^W0#P_%GY.OAYXC\G8MS-QVQR7?<F8A#N(=-D.:YJ+6,Q^O
M5,JELI":.#5554E]4&8X&U=A4VI9*3H#+>8'RY<F\P<TM[3(/,_R.XVXPMZ6
MEIW^#N/)U)78(55L=UBQGOJ4PB98OY`MP.2$R`XD*!"1VG;0#'E_TWGB2B,E
MJ!S3Y!0GVNQ<>0FPP=W\O(;(4W(9;.)-]JFUC=([AV]/JT!(GX?>#>=^*&3V
M%A9^9_D9S]A#V*+QRGXUY>LJJTQ['YIG0I+>0P)3*%3OST>+$5':;!0VEMY>
MX)VV`D+'J.@/7T/H?L/KTT!#)SY\HO(_)3(<WD<I>?\`Y8VF`Y?E-I?Q^)F+
M+'VL%HJN?8N3HF+1JP1_RUC44Z%I9CB4TL>TTGN25==`-_9_IO\`Q&;:0ASF
M;R%=<2/ONBSP5L+7N3WI;_DY0;2">B=^@&V@-_XL^1['X"MV;3@3SS\L>*6!
M91+&=3X_.QI%-:B/*:?>8L:B/$@5$C\XTV6G%F/W*0LD]QV(`GKT!Y'T@K!_
MU1^SU/I]NN*L8YR/<U%<W@O=ZCK6-KG<RUX4]']9KMWC&/9+$_3\BI:R]@[[
MF)<0HUFP2>F_MS6WTI5U]1L?MU;FX-F[3W9:+9;HQUGD+5RHJMGC;(E4U1=4
M[%X$[8WMYC5YK*62-_>CE11,G/'+@AQ7<KBC"P?J;J4-)]=^B&U)2.OV:QTO
MPX]"5:K?Y4PU'?\`KL*VS>&YXTHR^N$3]90'CCP0D;#BG#@/J_3!_P#<UUR?
M#9T%EC]D_:>$Y$[K9B?EH=B;TW4C>5+ZXY5_O'Z/CIP4KUXJPX[#8;U@Z#ZO
M]YKDGPW=!:(G\IX141*:VS%^HZF[OW.Q*-OKA$K^D=?_`$W\#_'BG#C^VMW_
M`.PN:BGPW]!4X;2P7_U8U^HYKO+="Z+?7'^T9NEX2X@QV4B=2\:X=7S6CNS*
M:I(CC[*O\S+CZ'2TH_6G8ZJF&Z%='-O3>\83;6'MIN]ENQ/J)2;<FX+AJLEO
M+A6KQ\:BG)0E&P3Z)2$CT_A'H-]MP!]FLIPPQ6\;8(&M9`RG*U$HUM.%$["A
MHCN3D<YSEKYE6KOG/WKM55<M5XA$1$H&H$37,FR_%\-KGK;*K^HQ^N825.2K
M6<S$20D;D,H6HN/.;?X4I4=`>ZDN:_(:FMO*B09=5;P(UE7R2RZR7XDM'O1G
M2V\&W6O=84E0"D@D:`RN@/)^>A?FQ7&=#%C[)DJKC)9_/&.#V&0F(5)D?E@L
M=%]NQT!Z]`&@#0!H`T`:`TG).1L)Q&=55609/45UK>3X=;45:Y*7[.?-GN_E
MHK,>MBEZ:M"WCU<*$H0!U.@-W(V)'U';0'&@#0!H`T`:`-`&@#0!H`T`:`-`
M&@#0&0T!Y7_XQ_LC^\Z`Z=`&@#0!H`T`:`-`&@."0`=QN#LD@^A[B$_Z?WZ`
MC4\K,7H^5?(KB/C"IKHW\PR$)FYK<-%S\VWCJG1(1#E%MY*4(:JX3RO0*_XA
M/4[Z`DG898AL1XD5E+$5EAJ/&920E#+,9`1'9;:)[D)0P!H#M^OJ!MMN20`-
M]]O4C?T^&@&]#QXIF^?/^?"L@N_U1R`J.N@46OTX2%50J"X)!<,DUYB[G\H$
MA/N[+)T`X3XD`$[;*.Q3Z$[%1&X("?CH#D[C?<*`&^ZBE7;TZ[[[=4_:.F@`
M$$`@[@^FW70",<P\W8OPK"QUR[@V]U,RR[;I*.EHD1EV4N4KL#CX,J1&;1'9
M4ZA!4%%2G'$@#J3H!8T+4IMMU32VBX@*+:@D+;5[86MM24DI[FNH/;N-P>N@
M.ST!.Y!'5.P!)._H`0=R1^S0$:&#XGC6;><N666.5$.'0<8M/SY?Y5M9CRLJ
M9CIK5S5NDK2F2Y=3'CMN-_R^XT!)@04[;@C<;]01\-]NNW4?9H#C0'`._P#"
M%'<)(Z%._=T`W7VCN!^'KH`W!W_U2=]ME$`;=2$E1'4CIZ_9H#]'IZD>@)Z]
M4]W\(4!U!)Z?MT!P.I*1N5#KV@$DCZ]AZ`'Z]M`<[';?X;;_`-NY3VGZE#;?
MZMNN@.#]U(5L2E1V!"5%/VJ*MNU*0!ON3MMZ:`X!)44]JOX0I)VW"P?0I[23
MU^W;0!W#8'KL=B#VG;90W2?3H%'I^W0'.@.-Q]8VW"22I([2K^'?<C^+X:`Y
MW'<4]P[@.XIW^\$[[;D>H!WT`:`-`9#0'E?_`(Q_LC^\Z`Z=`&@#0!H`T`:`
M-`&@/).FQ:V%+L9SB&84",_-F/K(2AB+%:6_(>43TV::;*O[-`10<&#D#F_E
M_ECD+%9"L>?OYC]2K/I$=,US"<8EO`BOQJ.\/8EY3:1(D=ELJ_"BQ@MP[*4D
M:`6OQ7BY+CW.7/&$/YED.;8SC"(D95M=S7YF]^J:R>Y0=>>:CS%1R\VM#/:C
M\'J-`.=YER')*#')$BIF-8W1Q:VTM<NSE:HRYF-4E;']PQZ"%([D3<CO)"TQ
MXRG![$?JM04=DD!`?!JMS&3A&6YYE-S>643-\B]_'F+VTE64E,&J_,Q)-D#(
M=6AE<V6XIM0;2A"O8[MNN@-X\FN;+KCF)C6$8$TU-Y/Y$FMUV.-*0E\5$=Z0
MB$;EV,X"AZ0N4Z&HZ5`H!"UJZ(V("'\T5EMXX8WQAFM9F66Y!R9-S>NC9C<V
M^0VTYG+82H4B1=5BJ.1*54LUJ5H2AA++2"SNGJ=]`2*!Q1C)>::"EJCJD-M*
M=#:?<6`XB.MS8AL[KVWZZ`B\NJK)?(;RLA8)G$Z$*/C*IEV-I'PMV;#8ISLS
M*_3FKI]9E2;5-D]';=EH;8W4VH(2`.[0&W<43;SC;R]R#ABIR7)KW`K*GD3C
M79+;OWSM5,3C[%\Q(1*F.O.)4TXXIDJ!!<;4GN'3?0#\,XRB+A.&Y1E\UQ+<
M?&Z*RMU%6VRUPXSCC#([NA+[X2@#X]V@(T_$C&<ZS^@S1^KM;/#J_+\FD3^0
M<[@I9.06`2RI]G$,0E2`I$.0_*L'Y-A.[%%AM2&D??.X`47Q1E9-1\\<Z<<_
MS5>Y1AF,N2VXSM[.D63[5C#N&8<5\OR%N>U(<BJ<:<"2E*RT#VC;0#XLZSC'
M..<9L,MRF9^3J:Y`!#8]V9/F/'LA5=;$2?=F6E@^0AEI`)43\-`-5Y:RCD>H
MXBR3E?-,QNN,)2J]O^1L`Q95>B5%LK):6Z6+EEO+B3)=Q<26S[DN*S[,>*D*
M`4LIWT!OWB7@-CA'#]/.OI,Z3DN<.',KE<Z9*ENLBT9:_3(V\EYX-J;K$-K7
MV]OXCBM_0:`0+S;R;.:K'=I&2S<0JIV2PZ;"Z/';9,61DL>%!%ED.69+/B+3
M-8BQ''FV8D%E0*"GW'2KN2`!D$\-<V<S83@>43.5KW`WJV+C:<=Q\JLD[4$"
M+&9.39"]7R8\F;F5XZU^;2VZ7&&F7`VKJ"=`/@R>3DE7C,A>,US.19,&8E?6
ML6$E,&([->=:AJM+)Q2AM71$.&1(2C=QQMLI1NI0T!%]@61\H95Y29778/F]
M]E4B'#M:*;D=J^^[B-<Z&(<*XR=O'8[B:MNIJ)_O)J(W;W/O^V%+4@+.@//C
MEOG\+RQO<5XIS7*<\=:C6E+:V^8VSUA4Q[!-<F->7EK"C>Q7?I>.V:TN,,LM
M(4Y(0ED'J=`*3Q+`R:;Y@9'$Q_D;,<PQ?!ZF4WGESD%J),6SO)45,.351:Z.
M45D6(+IS_AVVT)_+B.X`5="0)()4J-!BR9LQ]B-$B1WI,F3)=2Q'CL,-J<=>
M?>7LAIII"2I2CT"0=`-LC9GDG+$*RRVNR*;QMPC2B<_%R>$TPSE^=1JY)5-M
MX4FQ8D1L:Q)*67$L.AI4J80%)*$'J`CGAC3Y!EMWR-SAD]W?W@NI[V)8C)O9
M#BGWZ2`['<D3W8Z"W$2ZIIF+'[DMCN4TL]"3H!_N@#0&0T!Y7_XQ_LC^\Z`Z
M=`&@#0!H`T`:`-`&@&N^9.63L/X#RER`76Y&12*W%UOL]%,0K=Y1L27.@;]Z
M"PMKNZ[%S0&@81E^,<2\+87QYQ(:[.^6,CHHD^MHJ%UJ<[_,5Y%;D6&295(C
MK<CTM35+>^^92F_NM!"03OL`O'!/$R.(\.<K9T[]9R_(I[V1YQD*@%*M\AGG
MW9"6EJ_%_(PE+*&0H^FY_P`6@&Q>;F<-3Y>!<$MW<3'HV;V4&WS.\FNI9B0,
M<8EK9BLO.+V3^*\RZ^E/JMQA"$@E0&@'<\4*:7A-3$K\9D8ICE>TFLQ"#.5V
M6<G%X32&*^YLH!2AVMEVY[W_`&5A2PA:5+V62``U;)L>?L?/;#IU\$BJB\=K
MO,;1)41%7(J(4^/($9:T);]^)8SBXH`E020=M`8'-(DGRE\B,?I:!3DWB3AB
M8'LER5"N^MM<@_,M2Y5972#LW,DK=BMQPIHK2AMMPDCIN`_3*<AA8GCM]DU@
MMIBNQZGG74Q)(;"FH,:0_P!B5GHDNK0EO[2=`,&\,;6@@XIS+SIF]W`@3KW*
MY;UY/E3([:JJLBMBV4VO[Y4D39ED?;2`2[[8`Z]-`;WXUX-<97R#R!Y*Y772
M*Q6>RYD7`JNP86Q.C8HOV([%N^P\E+S*+"O@,(90L!1;W5L`1N!ZO-W))S7'
M>/<:T[J3D7*V65F/164$(5(@0W$29/M)/I[DU49I7UH)T!NN/<B\*\$8XOB:
M-DM<,DXWQQEZ9CS+<E-I<6TN.W*4Q![8P;L[V]LI2#^794XZ$OIW`&@._P`9
MN+;7`,:OLGR]E+/(/*-V]EN41]@I=2B?)DRJRA4XG[I>@-S%*>.X_$61_AWT
M`B'-')V*GRIP#%>0KF/2\?<<5/\`-CB;%#OZ;/S:=!DR*5^4&VG%2%1$^V(Z
M0#NZ%)'KOH!%^:N2AS)SIA6-YF96(\5XZJ/DK=-8-NHN;B"Y#<LF)=A2M`R'
M;W+X;2(U;![%.H0^-QWK.P$IN)S[.UQRKL;B@5B\Z8PMXX\X^W(?J8JG7!`B
M2W&4I93-$(-EY"/NMN$IW.V^@&#<AT?_`%"^7='@[W_$X/P[4,6.3)2XEUER
M=^8C3Y]:Z4C9+T^8N-"6#L2RR[]6@)&PE*4MMH"`E"$(2AM'8A(0.U*4('1*
M4@;`?`:`;]Y-<J-\3\2Y#;Q7VTY)=-?RWBC(/<^Y<6J%M*EQVT'W7#50PY(5
MV;[*0D';NT`W?&:N!XB>,5UFD]+9Y)S*#&7[DGM1*_7;AE:<>I4D[O+8HH[R
MI+Z=BIR07"?70'@P"D:\7?&K)^5[A"GN3\_KXSS3TA"E3&;._*OY;J4=P6Z%
MQW)*K&63U=<"MQN!H#;_``M@QZC$TLU<9-],R9I_+>1,Z2^W^39R"Q4EVDP^
M`\CN;N+"#6N*?L"VL(C.N[$E:N@'K\X,U728;@V#.3'JNHY'RMJORZT:"T/,
M8G5O1)5S&26P70V^)25K(Z]C9!.Q.@$5\JN:6+7!L6XXXI4U!XWNI<7&SEBD
MJKZ?((],B$DT](\XF.',<JD/,_G)B=FBHI;0H]JB0'L<!?IT/!(./8Y4O1<,
MQF-!I<:R&1WLJS=4=@KO<GBP76VY#%5+N5.",^Z.Z6D%P?<*20%PT`:`R&@/
M*_\`QC_9']YT!TZ`-`&@#0!H`T`:`-`8>_QZCRJIE4625,"\IY@2)-=91VY,
M5WL*2@EM8/:M"D`I4-E`^AT!A</X[P7CZ,]$PC$Z'%V9*NZ2:BO8C/R=U=Y3
M)E=JI+Z.[KLI9`^&V@-RT!IUQQ[@V09%59;>8G1VV34C26*FZGP&I,V"TATO
MMH96Z%(V9?/>WW)/MK^\G8]=`;B`!\.NP&Y))V`2/B?4A(W^O;0&I99@>&YW
M&C1,PQRKR%B&XIV(FQ8[W(KCB>QQ4:0VIN0P'$=%!*PE8]0=`9:BQ^CQBLCT
MN.5%=15$0?\`#UM5$9A0VCMLI26&4)3WK_Q*_B4?4Z`9]YS9E(J>,JSC^I>)
MR'DZ^@4<>"TL)D/5<>0W(EDH_B]J1+]AGZCWD:`63$_'WC&CQ_#:^VPO'+>Y
MQBDJH)LIM>S)=DS8#"2Y,D-K!CS743WG5(6^AQ22>AZ:`7,)2D!*0$I``"4C
M8)"0$@)`VV``V`^`T!A++&<>N;"KMK:EJ[*UHUK<I+*=`BR9U.Z[V%QZMDN-
M*=BNK+:25).^Z1]6@,*YQM@#N5G.G,/H',R]IIK^97*]ARV"64A#+@DN)41)
M:0`E+VWNI2``KH-`;L.AW]>@!W)V5]:E?6H_$_9H#2;;C;`+[)8&976(4%KE
M58TVQ7WL^N8DSXK3+A=90TMQ*D;LK/W%%)4C?H=`?M[CK!9.7-9[)Q2DDYHP
MRW'8R61`8=M6F64>VR$2%I.SC*/NH<V]Q"20E0'30&Y)';\225%1*NI4HG<D
M^GJ?[!Z#IH#"5F,XY2V%O;5%%4UMK?O)DWEE"@1HTZXD(*BAZQDM-I=EN(*U
M;%9/KH#.:`P%[BN,Y.(*<CQ^GO45DG\[7(M8$><B#+[2@R8J7T+##RD'8J3L
M2!UT!S?8MC64QXT7)J"HOXT*4B=$8MX$>>S'FH2M*9;34AM;:'TI<.Q`Z;]-
M`=>3XCC&:4KN.Y91UV04C[C+SM;9,!Z.7HY*F7D@%*FW6B?NJ204_#;0&1JJ
MBJHZV)3TU="JZJ`TB/"KX$=N+$B,-I"4M,,,I0A"`$C?IU(W.YWT!@\MP+"\
M]CP(F:8Q3Y-%JY?Y^O8MXJ9;467V]A?;2L]2I'10.Z5`#<=-`>3(.-./LKCT
MD3),-QZYB8VOOH8DVN97%JMPV%(B1T!#+;"PRCN;V+:NQ.Z>F@-S:9;80AMI
M*6VVD);;;0E"&VVT)2A#;:$)2EMM"$A*4@````#0';H`T!D-`=2_:W^_Z[?Z
MWIN?J^W0'X_`^G?H`_`^G?H`_`^G?H`_`^G?H`_`^G?H`_`^G?H`_`^G?H`_
M`^G?H`_`^G?H`_`^G?H`_`^G?H`_`^G?H`_`^G?H`_`^G?H#@^Q\-]_AV]_=
M_9_9H!@'(G_1E_.3W_,3^</YU_-_@?JO_-_]4][\^?8_1?C['Y[_`''Y3\/?
M;LZ;:`>]B7Z5_+M7^F_KOY'\N?RW\S?K7Z[[7N*__8_K_P#XS[O?O_\`D?>V
M^S0&Q?@?3OT`?@?3OT`?@?3OT`?@?3OT`?@?3OT`?@?3OT`?@?3OT`?@?3OT
M`?@?3OT`?@?3OT`?@?3OT`?@?3OT`?@?3OT`?@?3OT`?@?3OT`?@?3OT`?@?
-3OT`?@?3OT!Z-`?_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
